Bortezomib_COA_15827_MedChemExpress
硼替佐米杂质合集
中文名称
1
051B
硼替佐米
名称
硼替佐米杂质 湖北扬信医药科技有限公司
CAS
结构式
Bortezomib
179324-69-7
提供的图谱 HNMR,MS/LCMS/GCMS,HPLC/GC
2
0511B
硼替佐米
Bortezomib Impurity 1
289472-78-2
HNMR,MS/LCMS/GCMSFra bibliotekHPLC/GC
114457-94-2
HNMR,MS/LCMS/GCMS,HPLC/GC
5
0514B
硼替佐米
Bortezomib Impurity 4
886979-78-8
HNMR,MS/LCMS/GCMS,HPLC/GC
6
0515B
硼替佐米
Bortezomib Impurity 5
886979-81-3
HNMR,MS/LCMS/GCMS,HPLC/GC
7
0516B
硼替佐米
Bortezomib Impurity 6
3
0512B
硼替佐米
Bortezomib Impurity 2
289472-81-7
HNMR,MS/LCMS/GCMS,HPLC/GC
4
0513B
硼替佐米
Bortezomib Impurity 3
289472-80-6
HNMR,MS/LCMS/GCMS,HPLC/GC
扬信医药代理各品种杂质对照品 ：阿莫西林杂质，氨氯地平杂质，泊沙康唑杂质，马来酸氯那敏杂质 ，帕瑞考昔杂质，瑞格列奈杂质，瑞舒伐他汀杂质 ，索非 布韦杂质，索拉非尼杂质 ，替格瑞洛杂质，替若福韦杂质 ，头孢克圬杂质，依折麦布杂质等 ；并提供COA、NMR、HPLC、MS等结构确认图谱 。专业<杂质对照 品>解决方案，代理中检所/EP/BP/USP/LGC/TRC/DR/TLC/MC/SIGMA/BACGEM/STD 等品牌。
Bortezomib_SDS_MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Sep.-21-2017Print Date:Sep.-21-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :BortezomibCatalog No. :HY-10227CAS No. :179324-69-71.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureGHS Classification in accordance with 29 CFR 1910 (OSHA HCS)Acute toxicity, Oral (Category 2)Acute toxicity Dermal (Category 2)Acute toxicity Inhalation (Dusts/Mists) (Category 2)Specific target organ toxicity (repeated exposure) (Category 1)2.2 GHS Label elements, including precautionary statementsPictogramSignal word DangerHazard statement(s)H300 Fatal if swallowed.H315 Causes skin irritation.H373 May cause damage to organs through prolonged or repeated exposure.Precautionary statement(s)P201 Obtain special instructions before use.P202 Do not handle until all safety precautions have been read and understood.P264 Wash skin thoroughly after handling.P270 Do not eat, drink or smoke when using this product.P280 Wear protective gloves/ eye protection/ face protection.P301 + P312 IF SWALLOWED: Call a POISON CENTER or doctor/ physician if you feel unwell.P302 + P352 IF ON SKIN: Wash with plenty of soap and water.P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contactlenses, if present and easy to do. Continue rinsing.P308 + P313 IF exposed or concerned: Get medical advice/ attention.P321 Specific treatment (see supplemental first aid instructions on this label).P330 Rinse mouth.P332 + P313 If skin irritation occurs: Get medical advice/ attention.P337 + P313 If eye irritation persists: Get medical advice/ attention.P362 Take off contaminated clothing and wash before reuse.P405 Store locked up.P501 Dispose of contents/ container to an approved waste disposal plant.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:PS–341; PS341; PS 341Formula:C19H25BN4O4Molecular Weight:384.24CAS No. :179324-69-74. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Solid)Odor No data availableOdor threshold No data availablepH No data available Melting/freezing point No data available Boiling point/range No data available Flash point No data available Evaporation rate No data available Flammability (solid, gas)No data available Upper/lower flammability or explosive limits No data available Vapor pressure No data available Vapor density No data available Relative density No data available Water Solubility No data available Partition coefficient No data available Auto-ignition temperature No data available Decomposition temperature No data available Viscosity No data available Explosive properties No data available Oxidizing properties No data available 9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)UN number: 3249Class: 6.1Packing group: IIProper shipping name: Medicine, solid, toxic, n.o.s.(Bortezomib)Reportable Quantity (RQ):No data availablePoison Inhalation Hazard: NoIMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
西咪替丁的化学结构式
西咪替丁的化学结构式1. 西咪替丁的概述西咪替丁（Simvastatin）是一种用于降低胆固醇和脂蛋白水平的药物，属于他汀类药物。
它通过抑制胆固醇合成的关键酶HMG-CoA还原酶，从而减少胆固醇在体内的合成。
西咪替丁是一种处方药，常用于治疗高胆固醇和高脂蛋白血症，预防心血管疾病的发生。
2. 西咪替丁的化学结构式西咪替丁的化学名为(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-羟基-6-氧代-3,5-二甲基-4-甲硫基-4-氧代-5-氮-6-甲基-1,2,3,4-四氢-2-吡啶基]乙基}-3,7-二甲基-1,2,3,7,8,8a-六氢-1-萘酮。
西咪替丁的化学式为C25H38O5S，分子量为418.57 g/mol。
西咪替丁的结构式如下所示：3. 西咪替丁的合成途径西咪替丁的合成途径相对复杂，主要包括以下几个步骤：3.1 邻氨基苯甲酸的合成首先，通过邻氨基苯甲酸的合成作为起始原料。
邻氨基苯甲酸是通过对硝基苯甲酸的氢化还原得到的。
3.2 吡咯的合成邻氨基苯甲酸与乙酰乙酸乙酯反应生成吡咯化合物。
该反应需要碱催化。
3.3 吡咯的环化吡咯化合物通过烷基化反应得到环化产物。
该反应需要环化试剂和酸催化。
3.4 吡咯的氧化环化产物经氧化反应生成相应的醛。
该反应需要氧化剂。
3.5 醛的还原醛经还原反应生成相应的醇。
该反应需要还原试剂。
3.6 醇的酯化醇经酯化反应生成相应的酯。
该反应需要酯化试剂和酸催化。
3.7 酯的水解酯经水解反应生成相应的酸。
该反应需要水解试剂。
最终，通过以上合成步骤，得到西咪替丁。
4. 西咪替丁的药理作用西咪替丁通过抑制HMG-CoA还原酶的活性，阻断胆固醇的合成途径，从而降低体内胆固醇水平。
此外，西咪替丁还可以增加低密度脂蛋白受体的表达，促进低密度脂蛋白的清除，进一步降低胆固醇水平。
西咪替丁的主要药理作用包括：4.1 降低胆固醇水平西咪替丁通过抑制胆固醇的合成，可以显著降低总胆固醇、低密度脂蛋白胆固醇和甘油三酯的水平。
Bortezomib (PS-341)_蛋白酶体抑制剂_179324-69-7_Apexbio产品说明书
Bortezomib 有效抑制细胞生长，而其它化合物对细胞生长没有或 有很小的影响。在 9 个犬恶性黑色素瘤细胞系（CMM-1、CMM-2、 ChMC、KMeC、LMeC、OMJ、OMS、OMK 和 NML）中，bortezomib 抑制所有细胞系的生长，IC50 范围介于 3.5~5.6 nM 之间。
每个产品具体的储存和使用信息显示在产品说明书中。ApexBio 产品在推荐的条件下是稳定 的。产品会根据不同的推荐温度进行运输。许多产品短期运输是稳定的，运输温度不同于长 期储存的温度。我们确保我们的产品是在保持试剂质量的条件下运输的。收到产品后，按照 产品说明书上的要求进行储存。
ApexBio Techn
无胸腺裸鼠
0.8 mg/kg；静脉注射
在异种移植小鼠模型中评估 bortezomib 对 CMM-1 细胞的体内生 长抑制活性。在第 4 天的治疗后，bortezomib 显著抑制肿瘤生长 （P < 0.01，对照 vs. Bortezomib）。与对照相比，bortezomib 治疗 小鼠的肿瘤具有显著降低的有丝分裂指数（P <0.01）。同样的， bortezomib 治疗小鼠来源的肿瘤中，Ki67 指数也显著下降（P < 0.01）。
产品反馈
特别声明
产品仅用于研究， 不针对患者销售，望谅解。
HeLa cells were untreated (-) or treated with 10 μm PS-341 (+) as indicated, 4 h later the cells were harvested and the lysates were subjected to immunoblot analysis with anti-ubiquitin or anti-p53 antibodies.
吡唑衍生物类环氧合酶-2抑制剂研究进展
吡唑衍生物类环氧合酶-2抑制剂研究进展本文旨在综述近年来对吡唑衍生物类环氧合酶-2（PTP-2）抑制剂的研究进展。
PTP-2是一种重要的家族成员，被证明在肿瘤发展以及炎症、脂质代谢、免疫和神经退行性疾病方面发挥着重要作用。
为了利用PTP-2抑制剂开发出潜在的药物，人们已经构建了多种不同结构的吡唑衍生物抑制剂，并对其作用机理进行了详细研究。
基于由乙酰氧基的体内和体外酶活性研究所获得的数据，有一类吡唑衍生物–2-[2-(5,5-二季铵基)吡唑]化合物，具有分子内拓扑结构，能够抑制PTP-2的活性并阻止癌细胞的增殖。
此外，结构优化策略也是提高PTP-2抑制剂疗效和生物活性的重要手段。
最近，他们设计了多种新型带有双位超精细碱基底的双位咪唑衍生物，其中一些具有优良的PTP-2抑制活性和较高的药物动力学参数。
因此，该部分研究工作提供了有助于开发PTP-2抑制剂的重要依据和实用性指导，有望促进人类肿瘤疾病的治疗。
近年来，通过合成天然产物衍生物的策略，研究人员发现了不同的吡唑衍生物类环氧合酶-2（PTP-2）抑制剂，其中包括6-(β-D-吡唑糖基）-3，7-二羟基-4H-咪唑-3-甲酸酯，4-乙氧基-N，N，N-二甲基苯甲胺、4-氯-N，N，N-三甲基苯甲胺、3-乙氧基-4-甲基-N，N，N-三甲基苯甲胺和2-[2-(5,5-二季铵基)吡唑]化合物。
体外试验表明，上述抑制剂均有良好的PTP-2抑制活性，抑制比率高达91-99％。
此外，它们也可以有效抑制癌细胞的增殖，用于抑制乳腺癌，肝癌，肺癌和其他多种癌症细胞株的生长。
有趣的是，为了改善PTP-2抑制剂的抑制活性和生物活性，结构优化似乎是一种重要的策略。
一些学者将2-[2-(5,5-二季铵基)吡唑]化合物加以改造，以产生更为简单和灵活的结构，展示出优异的PTP-2抑制活性。
例如，2-[2-(6,6-二季铵基)吡唑]化合物的抑制活性比2-[2-(5,5-二季铵基)吡唑]化合物高出1.8倍，而4-[4-(4,4-二季铵基)吡唑]化合物的抑制活性比2-[2-(5,5-二季铵基)吡唑]化合物高出9.6倍。
Expression, Purification and Crystallization of
Expression, Purification and Crystallization of the Mycobacterium Tuberculosis HSP16.3 Molecular Chaperone Background of Mycobacterium Tuberculosis HSP16.3HSP16.3, a 16.3 kDa protein from Mycobacterium Tuberculosis, was originally identified as a prominent antigen (Kingston et al., 1987). During the stationary phase, HSP16.3 is maximally expressed and becomes a main protein of the latent phase (Yuan et al., 1996). Previous studies showed that HSP16.3 can make the cell structure stable and prevent stationary Mycobacterium Tuberculosis from autolysing (Cunningham et al., 1998). In previous studies, HSP16.3 was found as one of theα-crystallin-related small heat shock proteins (sHSP) with molecular chaperone activity. Experiments in vitro revealed that HSP16.3 can suppress the thermal aggregation of citrate synthase at 39.5˚C, without consumption of A TP (Chang et al., 1996).Now the Mycobacterium Tuberculosis HSP16.3 gene was cloned to the plasmid pSTE-HSP16.3, and transformed to E.Coli. BL21(DE3) strain.Material and MethodExpressionThings to have ready before Starting.-Plate or glycerol culture-Sterile LB 25ml in a 50mL shaker flasker, 250ml in a 500mL shaker flasker, all together autoclaved, antibiotic added afterword.- antibiotic and sterile water- TipsPrepare the LB and autoclave:Fomula of the LB medium for 1 Liter:Bacto Tryptone (BT) 10 gBacto Y east Extract (BYE) 10 gNaCl 10gThe LB medium, dd H2O and the tips all together autoclaved at 121 ˚C for 20 minutes.Method:1 Innoculate 25 ml LB Medium ( containing 100 ug) and grow culture overnight(37˚C, 200rpm).2 Next morning inoculate 250 ml prewarmed LB Medium ( containing 100 ug) with the 25 ml overnight culture and grow at 37 ˚C, 200rpm, HSP16.3 was overexpressed in soluble form intracellularly without IPTG induction.3 Incubate the Culture for 10 hours before havesting the cell at 4000 g for 20 minutes.4 Resuspend the cell pellet in 30 ml Butter A and freeze the Sample in -80˚C refigerator.PurificationDE52 Ion-Exchange columnThings to have ready before Starting.-Butter A: 50 mM Imidazole pH 6.5 (1 liter)-Butter B: 50 mM Imidazole pH 6.5 , 300mM NaClall together Fitrate with 0.2 um membrane.- DE52 medium , column ,Gradient maker, UV-monitor and Fractioner- TipsMethod:1 Thaw the cell pellet and vortex .2 Add 0.4ml 100 mM PMSF and sonicate (400kw, 4s-6s 50 cycle* 5 )3 Centrifuge 15000 rpm, 30 minutes to pellet debris4 Transfer supernatant to a 50 ml conicale tube and discard the pellet.5 The supernatant dilute to 50 ml with Buffer A and then load to DE52 ion-exchange columns (20ml), which was pre-equibrated with 100ml Buffer A. And then wash the unbound proteins with 100 ml Buffer A.6 Elute the protein with a linear gradient : 200ml buffer A plus 200ml buffer B, 2ml/min, 6ml each fraction.7 Run 15% SDS-PAGE to determine the HSP16.3 peak.Desalting by dialysis1 Preparation of the dialysis tubeCut the tube in a suitable length (20-30 cm)Boil the tube in solution containing 10 mM NaHCO3 for a few minutes.Boil the tube in solution containing 10 mM EDTA for a few minutes.Rasin the tube with de-ion water2 Pool the HSP16.3 peak and dialysis the Sample against 1000ml Buffer A for more than 6hours.Q-Separose (HP) Ion-Exchange Column1 load the sample to Q-Separose (HP) Ion-Exchange column (20ml), which was pre-equibrated with 100ml Buffer A. And then wash the unbound proteins with 100 ml Buffer A.2 Elute the protein with a linear gradient : 200ml buffer A plus 200ml buffer B, 2ml/min, 6ml each fraction.3 Run 15% SDS-PAGE to determine the purity of the HSP16.3 peak.Gel filtration ColumnThe HSP peak was a final volumn 0.3ml and then run though a Superdex75 (HR, 10/30mm) gel filtration column in 150mM NaCl and 5mM Imdazole, pH6.5. Crystallization1 The purified HSP16.3 was solvent-exchanged to water and concentrated to 20mg/ml before crystallization trails (Bradford). All the crystallization trials were carried out using the hanging-drop vapor-diffusion method at 291K: drops consisted of2 microlitres of HSP16.3 protein solution plus 2 microlitres of the precipitant. The drops were equilibrated against 0.2 ml precipitant at room temperature. The crystallization conditions were investigated with a PEG4000 Kit.Result and discussionThe purity of the final HSP16.3 was over 95% by SDS-PAGE. The crystallization trials of HSP16.3 yielded Cubic crystals with a size of 0.8*0.8*0.6mm in a few days.20040060080010001200mAUBuffer Tris-HCL pH 8.5 Precipitant PEG 4000 MethodV apor Diffusion Temperature 293 K Size0.8*0.8*0.6mmReferencesChang Z., Primm, T.P., Jakana J., Lee H. I., Serysheva I., Chiu W., Gilber H. F., Quiocho F. A., (1996) J Biol Chem 271:7218-7223Cunningham A. F., Spreadbury C. L., (1998) J. Bacteriol. 184:801-808Kingston A. E., Salgame P. R., Mitchison N.A., Colston M. J. (1987) Infect. Immun 55,3149-3154Yuan Y., Crane D. D., Barry C. E. III (1996) J Bacteriol178: 4484-4492。
荜茇明碱对人乳腺癌MDA—MB-231细胞放射增敏作用
基 金 项 目 ：江 苏 省 医 学 创 新 团 队 与 领 军 人 才 资 助 项 目
Ｉ Ｌ Ｊ ２ ０ １ １ ２ ３） Ｄ ＯＩ ： １ ０ ． ３ ９ ６ ９ ４． ｉ ｓ ｓ ｎ ． １ ０ ０ ８ — ７ ９ ４ Ｘ． ２ ０ １ ４ ． ０ ２ ． ０ １ ５
ｔ ｈ ａ ｎ ｔ ｈ ｏ ｓ ｅ ｏ ｆ ｒ ａ ｄ ｉ ａ ｔ ｉ ｏ ｎ ａ ｌ ｏ ｎ ｅ ｇ ｒ ｏ ｕ ｐ （ Ｐ＜０ ． ０ ５ ） ，
ｉ ｎ ｖ ｉ ｔ ｒ ｏ Ｙ Ａ０ 觎一 ｘ ｉ ｎ ， Ｙ Ａ ０ Ｚ ｈ ｉ － ｆ ｅ ｎ ｇ ， Ｌ １ Ｚ ｈ ａ ｎ － ｆ ｅ ｎ ｇ ， Ｌ Ｉ Ｕ Ｙ ｏ ｎ ｇ — ｂ ｉ ａ ｏ ．Ｄ ｅ ｐ ａ ｒ ｔ ｍ ｅ ｎ ｔ ｏ ｆＭｅ ｄ ｉ ｃ ａ ｌ ， ｍ
ｃ ｏ ｎ ｔ ｒ ｏ ｌ ，Ｘ— ｒ ａ ｙ ｅ ｘ ｐ ｏ ｓ ｅ，ｐ ｉ ｐ ｌ ａ ｒ ｔ ｉ ｎ ｅ ，ａ ｎ ｄ ｐ ｉ ｐ ｌ ａ ｒ ｔ ｉ ｎ ｅ ｃ ｏ ｍｂ ｉ ｎ ｅ ｄ ｗｉ ｔ ｈ Ｘ－ ｒ ａ ｙ ｓ ． Ｔ ｈ ｅ ｃ ｌ ｏ ｎ ｏ ｇ ｅ ｎ ｉ ｃ ａ ｓ ｓ ａ ｙ ｗａ ｓ ｐ ｅ ｒ ｆ ｏ ｒ ｍｅ ｄ
荜茇 明碱对人乳腺癌 Ｍ Ｄ Ａ — Ｍ Ｂ 一 ２ ３ １ 细胞放射 增敏作 用
姚建新， 姚 志峰 ， 李 占峰 ， 刘永彪
【 摘要 】 目的 探讨荜茇 明碱对人乳腺癌 ＭＤ Ａ． ＭＢ 一 ２ ３ １细胞 的放 射增敏作用及其可能机制 。方法
体 外 培 养 ＭＤ Ａ。 ＭＢ ２ ３ １细胞 ， 取 对 数 生 长 期 细 胞 进 行 实 验 。将 细 胞 分 为 对 照 组 、 Ｘ射 线 照 射 组 、 荜 茇 明碱 处理组 、 荜 茇 明 碱 联 合 Ｘ射 线 照 射 组 。 克 隆 集 落 形 成 法 分 析 荜茇 明碱 对 Ｍ Ｄ Ａ— ＭＢ ． ２ ３ １细胞 的放 射 增 敏 作 用， 按 多 靶 单 击 模 型 拟 合 细胞 存 活 曲线 ， 确定存活分数 （ Ｓ Ｆ ） 、 平均致死剂量 （ Ｄ 。 ） 、 准 阈剂 量 （ ） ， 计 算 放 射
硼替佐米杂质汇总
硼替佐米杂质列表集
中文名称 硼替佐米
英文名称 Bortezomib
CAS 179324-69-7
规格
10mg 25mg 50mg 100mg 更大规格请咨询
硼替佐米杂质1 Bortezomib Impurity 1 289472-78-2
10mg 25mg 50mg 100mg 更大规格请咨询
硼替佐米杂质2 Bortezomib Impurity 2 289472-81-7
10mg 25mg 50mg 100mg 更大规格请咨询
用途
项目报批 纯度高于98%
项目报批 纯度高于98%
项目报批 纯度高于98%
结构式
硼替佐米杂质3 Bortezomib Impurity 3 289472-80-6
10mg 25mg 50mg 100mg 更大规格请咨询
硼替佐米杂质4Βιβλιοθήκη Bortezomib Impurity 4 886979-78-8
10mg 25mg 50mg 100mg 更大规格请咨询
项目报批 纯度高于98%
项目报批 纯度高于98%
扬信医药代理各品种杂质对照品:舒更葡糖钠杂质，达托霉素杂质，依维莫司杂质，他克莫司杂质，阿奇霉素杂质，克拉维酸钾杂质， 红霉素杂质，克拉霉素杂质，林可霉素杂质，罗红霉素杂质，克林霉素杂质，恩曲他滨杂质，艾地那非杂质，瑞卢戈利杂质，艾氟康唑 杂质等；并提供COA、NMR、HPLC、MS等结构确证图谱。 专业<杂质对照品>解决方案，代理中检所/EP/BP/USP/LGC/TRC/DR/TLC/MC/SIGMA/BACHEM/STD等品牌。